CORT
The clock is now the story
Corcept Therapeutics is back in the headlines, but not because of a shiny drug update or a surprise earnings beat. This time, it’s a class-action reminder: investors who say they were hurt during the alleged relacorilant mess have a April 21, 2026 lead plaintiff deadline to get in line.
Why investors should care
The lawsuit centers on claims that Corcept allegedly overstated the strength of its Phase 3 relacorilant data while the FDA was allegedly signaling the evidence wasn’t good enough. Then came the big gut punch: on December 31, 2025, Corcept disclosed it had received a Complete Response Letter from the FDA, and the stock got chopped in half like it owed somebody money.
The not-so-fun part
Legal overhangs don’t always move a stock day to day, but they can absolutely keep sentiment muddy. If you’re a shareholder, this is the kind of headline that reminds the market the relacorilant saga is still very much in the room.
Big picture
This isn’t a fresh scientific readout — it’s the aftermath. And in biotech, the aftermath can linger as long as the actual drug development drama.